C4 Therapeutics
CCCC
114 hedge funds and large institutions have $353M invested in C4 Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 31 reducing their positions, and 16 closing their positions.
614% more call options, than puts
Call options by funds: $257K | Put options by funds: $36K
52% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 31
19% more capital invested
Capital invested by funds: $298M → $353M (+$55.1M)
1.5% more ownership
Funds ownership: 80.81% → 82.31% (+1.5%)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
1% more funds holding
Funds holding: 113 → 114 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.9M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$12M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$8.18M |
| 4 |
Goldman Sachs
New York
|
+$3M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.7M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$7.79M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.32M |
| 4 |
Millennium Management
New York
|
-$3.21M |
| 5 |
RI
RTW Investments
New York
|
-$2.86M |
CCCC Hedge Fund Activity: Q3 2022 in Review
114 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q3 2022, worth a combined $353M — up 19% from $298M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CCCC positions and 16 closed out — a net gain of 1 holder — while 47 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $12.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $14.7M.
- 114 institutional investors held C4 Therapeutics (CCCC) as of Q3 2022, up from 113 in Q2 2022.
- Funds reported $353M of C4 Therapeutics stock for Q3 2022, up 19% quarter-over-quarter.
- 17 funds opened new C4 Therapeutics positions in Q3 2022 and 16 closed out, a net change of +1 holder.
- The largest C4 Therapeutics buyer in Q3 2022 was State Street, an estimated $12.9M added.
- The largest C4 Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $14.7M sold.
Based on aggregated 13F filings for Q3 2022.